The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $145,336 Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective March 1, 2025 through February 28, 2027. The award supports research focused on "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors." The goal is to explore how modulating the metabolic regulator mTORC1 in hepatic macrophages can overcome the impaired CD8+ T cell priming observed in B-catenin-driven hepatocellular carcinomas, a type of "immune desert" tumor. The research will determine how TSC1-deficient hepatic macrophages can function as more effective antigen-presenting cells to activate anti-tumor CD8+ T cell immunity, based on their altered metabolic state. Successful completion of this project is expected to provide mechanistic insights into metabolic control of macrophage functions in cancer and identify a potential therapeutic strategy to address immune evasion in certain tumor types.
Generated 3/18/25, 3:02 AM